Current Report Filing (8-k)
March 17 2017 - 5:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON
,
D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): March 15, 2017
BioCryst Pharmaceuticals,
Inc.
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
000-23186
|
62-1413174
|
(State or Other Jurisdiction
|
(Commission
|
(IRS Employer
|
of Incorporation)
|
File Number)
|
Identification No.)
|
4505 Emperor Blvd., Suite 200
Durham, North Carolina 27703
(Address of Principal Executive Offices)
(919) 859-1302
(Registrant’s telephone number,
including area code)
________________________________________
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2 below):
|
[_]
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
[_]
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
[_]
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 210.14d-2(b))
|
|
[_]
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 1.01. Entry into a Material
Definitive Agreement.
On March 15, 2017, BioCryst Pharmaceuticals,
Inc.(the “Company”) entered into a registration rights agreement (the “Registration Rights Agreement”)
with 667, L.P. and Baker Brothers Life Sciences, L.P. (collectively, the “Baker Entities”), both of which are existing
stockholders of the Company. Under the Registration Rights Agreement, the Company agreed that, if at any time and from time to
time after May 12, 2017, the Baker Entities demand that the Company register for resale under the Securities Act of 1933, as amended
(the “Securities Act”), the shares of the Company’s common stock held by the Baker Entities, the Company would
be obligated to effect such registration. The Company’s registration obligations under the Registration Rights Agreement
cover all shares of the Company’s common stock now held or later acquired by the Baker Entities, will continue in effect
for up to ten years, and include the Company’s obligation to facilitate certain underwritten public offerings of its common
stock by the Baker Entities in the future. The Registration Rights Agreement is filed as Exhibit 10.1 hereto and the foregoing
description of the Registration Rights Agreement is qualified in its entirety by reference to such exhibit.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
|
|
Description
|
10.1
|
|
Registration Rights Agreement, dated March 15, 2017, by and
between BioCryst Pharmaceuticals, Inc., 667, L.P., and Baker Brothers Life Sciences, L.P.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 17, 2017
|
|
BioCryst Pharmaceuticals, Inc.
|
|
|
|
|
By:
|
/s/ Alane Barnes
|
|
|
Alane Barnes
|
|
|
Vice President, General Counsel, and Corporate Secretary
|
|
|
|
EXHIBIT INDEX
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Sep 2023 to Sep 2024